Tissue Phenomics Blog


Posts by Topic

see all

Topics:  personalized medicine, companion diagnostics, Companion Diagnostic Development, biomarker datafication, patient stratification, Biomarker Datafication Services

Powerful, Data Driven Patient Stratification - Improving biomarker performance.

Aug 26, 2015 5:00:00 PM

Personalized v. Standard Care

Why do Pharma companies care about personalized medicine given that this might limit the population for which their drug is approved?

Low response rates to therapy and lack of patient benefit compared to the standard of care can put success of a clinical trial and overall drug development at risk. Therefore pharma companies are invested in diagnostic programs to:

  • select the right patients for their drug
  • minimize the risk of drug failure
  • get drugs to market faster
Read More

Topics:  clinical trials, tissue phenomics, Common, patient stratification

Design and Implement More Efficient Clinical Trials With Tissue Phenomics™

Apr 23, 2014 8:32:00 PM

Late phase failure is a huge challenge for pharmaceutical companies running clinical trials. In fact, only 65% of phase III trials successfully lead to new drugs being approved (1). The primary reason behind this high failure rate is efficacy, with more than 60% of those phase III failures caused by poor response rates in large patient groups (2).

To address these low efficacy rates, more pharmaceutical companies have begun focusing their resources on solutions which ensure more confident go/no-go decision making. They recognize that the ability to select the right drug candidates for phase III trials and develop companion diagnostics for better patient stratification are the only way to gain this confidence and ultimately increase the efficacy of their drugs during clinical trials.

Read More

Topics:  big data, clinical trial, tissue phenomics, tissue diagnostics, companion diagnostics, patient stratification, diagnostics

Tissue Phenomics™: The Future of Big Data for Diagnostics

Mar 12, 2014 7:42:00 PM

When you hear the term “Big Data”, most people think of the huge volumes of structured or unstructured data from different sources. For diagnostics, extracting meaningful information from big data offers the great potential of detecting novel biomarkers to provide targeted patient treatment.

Tissue Phenomics™ is a big data approach to clinical oncology that enables all of the data in tissue images to be fully quantified in context. This automated quantification takes all standard pathological tissue biomarkers used to make diagnoses plus new complex tissue signatures – which often are difficult to assess with the human eye – and makes them available for bioinformatic analysis.

The core of Tissue Phenomics™ is the Definiens' Cognition Network Technology® (CNT) which has been used by many researchers on a small data scale.

Read More